首药控股2024年营业收入降24.6%，亏损扩大至2.12亿元

财中社2025-04-27

4月27日，首药控股(688197)公布2024年年报，公司营业收入为394万元，同比下降24.6%；归母净利润自去年同期亏损1.86亿元变为亏损2.12亿元，亏损额进一步扩大；扣非归母净利润自去年同期亏损1.99亿元变为亏损2.35亿元，亏损额进一步扩大；经营现金流净额为-1.97亿元，同比下降9.6%；EPS(全面摊薄)为-1.4251元。其中第四季度，公司营业收入为14万元，同比下降...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530966480?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-27 16:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530966480","market":"sh","top_or_hot":-1,"title":"首药控股2024年营业收入降24.6%，亏损扩大至2.12亿元","media":"财中社","content":"<div>\n<p>4月27日，首药控股(688197)公布2024年年报，公司营业收入为394万元，同比下降24.6%；归母净利润自去年同期亏损1.86亿元变为亏损2.12亿元，亏损额进一步扩大；扣非归母净利润自去年同期亏损1.99亿元变为亏损2.35亿元，亏损额进一步扩大；经营现金流净额为-1.97亿元，同比下降9.6%；EPS(全面摊薄)为-1.4251元。其中第四季度，公司营业收入为14万元，同比下降...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427164950a6ca3594&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>首药控股2024年营业收入降24.6%，亏损扩大至2.12亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n首药控股2024年营业收入降24.6%，亏损扩大至2.12亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-27 16:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427164950a6ca3594&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月27日，首药控股(688197)公布2024年年报，公司营业收入为394万元，同比下降24.6%；归母净利润自去年同期亏损1.86亿元变为亏损2.12亿元，亏损额进一步扩大；扣非归母净利润自去年同期亏损1.99亿元变为亏损2.35亿元，亏损额进一步扩大；经营现金流净额为-1.97亿元，同比下降9.6%；EPS(全面摊薄)为-1.4251元。其中第四季度，公司营业收入为14万元，同比下降...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427164950a6ca3594&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688197","symbol_name":"首药控股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427164950a6ca3594&s=b","article_id":"2530966480","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250427164950a6ca3594&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530966480","pubTimestamp":1745742835,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月27日，首药控股公布2024年年报，公司营业收入为394万元，同比下降24.6%；归母净利润自去年同期亏损1.86亿元变为亏损2.12亿元，亏损额进一步扩大；扣非归母净利润自去年同期亏损1.99亿元变为亏损2.35亿元，亏损额进一步扩大；经营现金流净额为-1.97亿元，同比下降9.6%；EPS为-1.4251元。截至四季度末，公司总资产9.22亿元，较上年度末下降17.1%；归母净资产为8.09亿元，较上年度末下降20.8%。文章来源：财中社首药控股2024年营业收入降24.6%，亏损扩大至2.12亿元","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"688197":"首药控股"},"translate_title":"Shouyao Holdings' operating income will drop by 24.6% in 2024, and its loss will expand to 212 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688197":1},"content_text":"4月27日，首药控股(688197)公布2024年年报，公司营业收入为394万元，同比下降24.6%；归母净利润自去年同期亏损1.86亿元变为亏损2.12亿元，亏损额进一步扩大；扣非归母净利润自去年同期亏损1.99亿元变为亏损2.35亿元，亏损额进一步扩大；经营现金流净额为-1.97亿元，同比下降9.6%；EPS(全面摊薄)为-1.4251元。其中第四季度，公司营业收入为14万元，同比下降38.0%；归母净利润自去年同期亏损4952万元变为亏损5196万元，亏损额进一步扩大；扣非归母净利润自去年同期亏损5843万元变为亏损6290万元，亏损额进一步扩大；EPS为-0.3494元。截至四季度末，公司总资产9.22亿元，较上年度末下降17.1%；归母净资产为8.09亿元，较上年度末下降20.8%。公司在2024年年度报告中提到，核心自研产品的研发进展持续推进，特别是SY-707的新药上市申请（NDA）已正式递交，预计2025年内完成另一款核心候选药物SY-5007的上市申请。同时，包括SY-3505在内的6款自主创新产品正在临床开发，19项临床试验在国内多个中心快速推进。报告期内，多个候选药物的早期研究成果在国际学术期刊和会议上展示，显示出良好的市场潜力。管理层强调，尽管面临行业竞争和政策压力，公司将继续加大研发投入，预计2025年研发资金将增加至2.3亿元，提升研发效率和产品质量。公司在保持核心技术竞争力的同时，计划进一步拓展在大分子药物领域的研发，致力于为患者提供更多创新的治疗方案。文章来源：财中社原标题：首药控股2024年营业收入降24.6%，亏损扩大至2.12亿元","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530966480","isCrawlerRequest":true}